BEDFORD, MA — Lantheus Holdings Inc. (Nasdaq: LNTH) is growing its presence in Bedford, leasing an additional 41,000 square feet of office space at The Core @ Crosby, according to reporting by the Boston Business Journal.
The new offices at 34 Crosby Drive are located just one mile from the company’s headquarters at 201 Burlington Road. In a statement to the Business Journal, Lantheus said the expansion is intended to “accommodate hires over the past couple of years and some of our remote employees are choosing to return to the office.”
The Core @ Crosby is a nine-building, 592,000-square-foot life sciences campus that features a mix of lab and office space. The campus is owned by Anchor Line Partners and Alloy Properties, who also manage other properties in Bedford, Lexington, and Waltham.
Anchor Line is a Boston-based real estate investment firm managing $1.2 billion in commercial assets. Alloy Properties was formed by TPG Real Estate in 2020 to invest in life sciences hubs in markets like Boston.
The new lease adds to Lantheus’ already significant local footprint. The company owns 354,000 square feet of manufacturing, laboratory, and office space in North Billerica. As of late 2024, it also leased 88,200 square feet in Bedford for executive, lab, and office functions, BBJ reported.
Lantheus has been steadily growing its workforce in recent years. The company reported 808 employees at the end of 2024, up from 834 in 2023 and 698 in 2022, reflecting its expanding operations and increased demand.
Since acquiring Progenics Pharmaceuticals in 2020, Lantheus has focused heavily on rebuilding and expanding its research and development pipeline. That deal brought with it Pylarify, a prostate cancer imaging agent that surpassed $1 billion in net sales in 2024, according to BBJ.
With strong revenue from Pylarify, Lantheus has been on an acquisition spree. In 2025, the company finalized its purchase of Evergreen Theragnostics Inc., marking its fifth deal since January 2024. The company’s acquisitions and in-licensing agreements in 2024 alone added five new assets to its growing portfolio.
Lantheus’ continued expansion underscores the increasing demand for radiopharmaceuticals in cancer diagnostics and treatment, and positions the company as a key player in Greater Boston’s booming life sciences ecosystem.
